Edition:
United States

AbbVie Inc (ABBV.K)

ABBV.K on New York Consolidated

96.55USD
14 Dec 2017
Change (% chg)

$-0.80 (-0.82%)
Prev Close
$97.35
Open
$97.33
Day's High
$97.44
Day's Low
$96.07
Volume
804,159
Avg. Vol
6,139,861
52-wk High
$98.87
52-wk Low
$59.27

Latest Key Developments (Source: Significant Developments)

Abbvie's upadacitinib meets primary endpoint in phase 2b study in atopic dermatitis
Thursday, 7 Sep 2017 08:03am EDT 

Sept 7 (Reuters) - Abbvie Inc :Abbvie's upadacitinib (abt-494) meets primary endpoint in phase 2b study in atopic dermatitis.Abbvie Inc - "‍look forward to advancing upadacitinib to phase 3 studies in 2018"​.Abbvie Inc - ‍upadacitinib is not approved by regulatory authorities and safety and efficacy have not been established​.Abbvie-‍results showed that primary, secondary endpoints, patients treated with upadacitinib achieved improvements that were statistically significant.Abbvie Inc - ‍in study, no new safety signals were detected​.  Full Article

Abbvie submits NDA to U.S. FDA for investigational oral treatment Elagolix for management of endometriosis with associated pain
Wednesday, 6 Sep 2017 08:01am EDT 

Sept 6 (Reuters) - Abbvie Inc ::Abbvie submits new drug application to U.S. FDA for investigational oral treatment Elagolix for the management of endometriosis with associated pain.Abbvie Inc - ‍submitted NDA to U.S. Food and drug administration for Elagolix​.  Full Article

Inventiva and AbbVie extend agreement
Monday, 4 Sep 2017 01:31am EDT 

Sept 4 (Reuters) - INVENTIVA SA ::INVENTIVA AND ABBVIE EXTEND AGREEMENT TO DISCOVER NEW POTENT ORALLY-AVAILABLE SMALL MOLECULE RORΓ INVERSE AGONIST DRUG CANDIDATES.INVENTIVA WILL RECEIVE AN UNDISCLOSED RESEARCH PAYMENT‍​.INVENTIVA WILL RECEIVE MILESTONE PAYMENTS WHEN A NEW CANDIDATE IS IDENTIFIED‍​.INVENTIVA WILL ALSO BE ELIGIBLE FOR DEVELOPMENT AND SALES MILESTONES AS WELL AS ROYALTIES ON SALES‍​.  Full Article

Abbvie says HUMIRA will now be reimbursed in British Columbia, Ontario, New Brunswick, Newfoundland, Labrador, Saskatchewan, Yukon
Tuesday, 29 Aug 2017 08:00am EDT 

Aug 29 (Reuters) - Abbvie Inc ::Abbvie Inc - HUMIRA will now be reimbursed in British Columbia, Ontario, New Brunswick, Newfoundland and Labrador, Saskatchewan and Yukon.Abbvie Inc - HUMIRA is also now covered by federal non-insured health benefits program.  Full Article

U.S. FDA says approved Abbvie's Mavyret for Hepatitis C
Thursday, 3 Aug 2017 03:22pm EDT 

Aug 3 (Reuters) - U.S. Food and Drug Administration ::FDA approves Mavyret for Hepatitis C ‍​.U.S. FDA- FDA granted the application priority review, breakthrough therapy designations, granted approval of Mavyret to Abbvie Inc ‍​.  Full Article

U.S. FDA expands approval of Imbruvica for treatment of adult patients with cGVHD
Wednesday, 2 Aug 2017 11:39am EDT 

Aug 2 (Reuters) - U.S. Food and Drug Administration::Expanded the approval of Imbruvica (ibrutinib) for the treatment of adult patients with chronic graft versus host disease.Says granted the approval of Imbruvica to Pharmacyclics LLC.  Full Article

EC grants Abbvie's Maviret marketing authorization for treatment of Chronic Hepatitis C
Friday, 28 Jul 2017 10:57am EDT 

July 28 (Reuters) - Abbvie Inc ::European Commission grants Abbvie's Maviret (glecaprevir/pibrentasvir) marketing authorization for the treatment of Chronic Hepatitis C in all major genotypes (GT1-6).‍Approval of Maviret is supported by data from eight registrational studies in Abbvie's clinical development program​.  Full Article

Abbvie CEO says "big" M&A is something that is not fundamental to their strategy
Friday, 28 Jul 2017 10:21am EDT 

July 28 (Reuters) - Abbvie Inc :Abbvie CFO: humira u.s. Sales increased 18 percent compared to the prior year, driven by low double-digit prescription growth plus price..Abbvie CFO: in the coming weeks, we expect U.S. and European regulatory decisions for our next-generation HCV treatment: conf call.Abbvie CFO says expect to see meaningful sales contribution from next-gen hep c treatment starting in 2018.Abbvie CEO: "even though we see (Humira) biosimilars...it will be our goal to maintain our leadership position within this market".Abbvie: despite Humira success, co still only has roughly 1/3 of the market; with 2 other similar drugs-in-development, there is opportunity to significantly grow market share.Abbvie CEO says he primarily focused on individual assets that can fill out their portfolio, when asked about M&A.Abbvie CEO says "big" M&A is something that is not fundamental to their strategy.Abbvie CEO: "it's probably going to be a difficult situation to sustain over the longer term but we need to work through that", when asked about androgel case.Abbvie CEO says 35 percent discount on second Remicade biosimilar did not surprise him at all.  Full Article

AbbVie reports second-quarter 2017 financial results
Friday, 28 Jul 2017 07:42am EDT 

July 28 (Reuters) - Abbvie Inc :AbbVie reports second-quarter 2017 financial results.Reaffirms FY 2017 gaap earnings per share view $4.55 to $4.65.Q2 adjusted earnings per share $1.42.Q2 GAAP earnings per share $1.19.Q2 earnings per share view $1.40 -- Thomson Reuters I/B/E/S.Reaffirms FY 2017 adjusted earnings per share view $5.44 to $5.54.Q2 revenue $6.944 billion versus I/B/E/S view $6.93 billion.AbbVie inc - ‍confirms 2017 GAAP diluted EPS guidance range of $4.55 to $4.65​.AbbVie Inc - ‍second-quarter global Humira sales of $4.716 billion increased 13.7 percent on a reported basis​.FY2017 earnings per share view $5.53 -- Thomson Reuters I/B/E/S.AbbVie Inc - ‍2017 adjusted diluted EPS guidance excludes $0.89 per share of intangible asset amortization expense and other specified items​.AbbVie Inc - ‍second-quarter global IMBRUVICA net revenues were $626 million, an increase of 42.6 percent​.  Full Article

CytomX achieves development milestone in collaboration with AbbVie
Thursday, 29 Jun 2017 08:00am EDT 

June 29 (Reuters) - CytomX Therapeutics Inc ::CytomX achieves development milestone in strategic oncology collaboration with AbbVie for CD71-targeting probody drug conjugate.CytomX Therapeutics Inc - will receive a $15 million milestone payment from AbbVie as part of 2016 strategic oncology collaboration between companies.  Full Article

BRIEF-Imbruvica Plus Rituximab Phase 3 Innovate Trial In Rare Waldenström's Macroglobulinemia Met Primary Endpoint

* IMBRUVICA® (IBRUTINIB) PLUS RITUXIMAB PHASE 3 INNOVATE TRIAL IN RARE WALDENSTRÖM'S MACROGLOBULINEMIA MET PRIMARY ENDPOINT